Aster DM Healthcare Limited

INR 4,070

. : 7.8 Mn India : 1.5 Mn4 Largest Number of Medical Centers/Polyclinics 5,478 Cr Revenue5 GCC : INR 4,070 Cr India : INR 1,408 Cr 769 Total Facilities Net Unit Additions in FY23 Q2 Total : 1 Hospital (181

INR 1,408

5 Mn4 Largest Number of Medical Centers/Polyclinics 5,478 Cr Revenue5 GCC : INR 4,070 Cr India : INR 1,408 Cr 769 Total Facilities Net Unit Additions in FY23 Q2 Total : 1 Hospital (181 Beds) | 38 Pharmacie

rs6

Patient Experience Centers One of the Largest Chain of Pharmacies 28,428* Human Resources Doctors6 : 3,622 : 8,095 Nurses Others7 : 12,983 Outsourced : 3,728 Geographical Footprint 6 United Arab

rs7

of the Largest Chain of Pharmacies 28,428* Human Resources Doctors6 : 3,622 : 8,095 Nurses Others7 : 12,983 Outsourced : 3,728 Geographical Footprint 6 United Arab Emirates H(9) C(96) P(222) King

Rs. 2,796

and Profitability Snapshot – FY23 Q2 Revenue from Operations ▪ Revenue excluding new hospitals4 is Rs. 2,796 Crs. (Growth of 12 %) EBITDA (excl. Other Income) ▪ EBITDA excluding new hospitals4 is Rs. 342 Cr

12 %

– FY23 Q2 Revenue from Operations ▪ Revenue excluding new hospitals4 is Rs. 2,796 Crs. (Growth of 12 %) EBITDA (excl. Other Income) ▪ EBITDA excluding new hospitals4 is Rs. 342 Crs. (Neutral compared

Rs. 342

s. 2,796 Crs. (Growth of 12 %) EBITDA (excl. Other Income) ▪ EBITDA excluding new hospitals4 is Rs. 342 Crs. (Neutral compared to FY22 Q2) PAT (Post-NCI) ▪ PAT (Post-NCI) excluding new hospitals4 is Rs.

Rs. 88

42 Crs. (Neutral compared to FY22 Q2) PAT (Post-NCI) ▪ PAT (Post-NCI) excluding new hospitals4 is Rs. 88 Crs. (De-growth of 18 %) ▪ Revenue for FY23 Q2 includes Covid Testing and vaccination income of Rs.

18 %

to FY22 Q2) PAT (Post-NCI) ▪ PAT (Post-NCI) excluding new hospitals4 is Rs. 88 Crs. (De-growth of 18 %) ▪ Revenue for FY23 Q2 includes Covid Testing and vaccination income of Rs. 41 Crs ; this was Rs.

Rs. 41

88 Crs. (De-growth of 18 %) ▪ Revenue for FY23 Q2 includes Covid Testing and vaccination income of Rs. 41 Crs ; this was Rs. 223 Crs in FY22 Q2 ; gross profit margin for this revenue was approximately 50%

Rs. 223

18 %) ▪ Revenue for FY23 Q2 includes Covid Testing and vaccination income of Rs. 41 Crs ; this was Rs. 223 Crs in FY22 Q2 ; gross profit margin for this revenue was approximately 50% with minimal indirect

50%

41 Crs ; this was Rs. 223 Crs in FY22 Q2 ; gross profit margin for this revenue was approximately 50% with minimal indirect costs Constant currency growth of Revenue, EBITDA and PAT (Post-NCI) is 7%, -

Source

1

Source

1. english.alarabiya.net 2. worldpopulationreview.com 3. 4. omanobserver.com edsfze.com (INDIA) t n e r r u C s u t a t S y a W d r a w r o F ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ ◼ *214 pharmacies in India operated by ARPPL under brand license from Aster Aster - Awards & Service Excellence 20 Dr. Azad Moopen • • • • • Alisha Moopen • • • • • • 6 JCI Accredited Aster Hospital Mankhool, Qusais and Day Care Surgery Centre in UAE “Saudi Central Board for Accreditation for Healthcare Institutions (CBAHI)” NABH and NABL Accreditations JCI Accredited HIMMS Accreditation (Stage 6) Aster Mankhool Aster - Awards UAE Innovation Award Dubai Quality Award DQA - DQAA Times All India Multispecialty Hospitals Ranking Survey 2021 Aster Medcity Aster CMI, MIMS Calicut and Aster RV IHF ICC Healthcare Excellence Awards Aster CMI, Aster Medcity and Aster Prime Hospital The Economics Times Healthcare Awards World Stroke Association Rating Newsweek World’s Best Hospitals International Best Practices ACE recognition by CAHO for C